RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 146 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.32 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,937 | -33.0% | 906,767 | -34.6% | 0.25% | -30.8% |
| Q2 2023 | $10,353 | +11.8% | 1,385,950 | 0.0% | 0.36% | -10.2% |
| Q1 2023 | $9,259 | -99.9% | 1,385,950 | 0.0% | 0.40% | -24.2% |
| Q4 2022 | $10,685,675 | -27.5% | 1,385,950 | 0.0% | 0.53% | -36.7% |
| Q3 2022 | $14,747,000 | +561.9% | 1,385,950 | +406.5% | 0.84% | +419.3% |
| Q2 2022 | $2,228,000 | +13.7% | 273,650 | 0.0% | 0.16% | +89.4% |
| Q1 2022 | $1,959,000 | -56.0% | 273,650 | +5.3% | 0.08% | -47.2% |
| Q4 2021 | $4,453,000 | -25.5% | 259,941 | 0.0% | 0.16% | -17.0% |
| Q3 2021 | $5,981,000 | – | 259,941 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |